Pack Ventures

The firm is not a formal university entity but focuses its entire investment mandate on companies founded by University of Washington students, faculty, and alumni. Its portfolio draws from the university’s research output, particularly in computer science, bioengineering, and medical sciences, with holdings such as Archon Biosciences, Phase Genomics, and Turion Space all connected to UW labs or graduates.

Pack Ventures discloses no fixed policy on leading versus participating. Its position as a first-check provider into UW-affiliated startups suggests it often enters at the seed or start-up stage, but the firm’s website does not specify target ownership stakes, typical check sizes, or whether it reserves capital for follow-on investments.

Sourcing relies on proximity to the University of Washington ecosystem — faculty relationships, alumni networks, and on-campus startup competitions. The firm brands itself as community-driven and roots nearly every portfolio company in a UW affiliation, a model that gives it early visibility into university spinouts before they reach broader venture markets.

The portfolio concentrates on AI and machine learning, life sciences and biotech, and deep-tech including space systems, robotics, and advanced materials. Representative investments include Cimba AI for enterprise decision tools, Cyclera Therapeutics for drug chemistry, Enosemi for photonic interconnects, and Outbound AI for healthcare revenue-cycle automation.

No public filing or announcement confirms a fund structure, vintage, or target size. The firm describes itself as a community-driven venture investor, but regulatory disclosures, Form ADV filings, and press coverage that would substantiate a committed fund structure are not currently available (Altss estimate).

The portfolio composition implies co-investor activity, but no named co-investors — such as other venture funds, corporate venture arms, or angel syndicates — are disclosed on the firm’s website. The absence of published deal announcements limits visibility into syndicate partners, round sizes, or board participation.

Nearly all named portfolio companies are headquartered in Washington State, with Seattle as the anchor. A few companies maintain operations in California or other U.S. locations due to commercial partnerships, but the investment thesis is explicitly tied to the Seattle-based University of Washington ecosystem.